Strong sales of several new drugs, particularly its hot new hepatitis medicine, lifted Johnson & Johnson's second-quarter profit by 13 percent, topping analysts' expectations.
The world's biggest maker of health care products raised its 2014 profit forecast for the second time since January, again up by a nickel to a new range of $5.85 to $5.92 per share, excluding one-time items.
Still, J&J shares fell in midday trading after company officials cited two drags on second-half revenue: the June 30 sale of its Ortho-Clinical Diagnostics business for about $4 billion, and expected new competition for Olysio, J&J's new treatment for chronic hepatitis C. In midday trading, shares were down $1.71, or 1.6 percent, at $103.67.
J&J on Tuesday reported earnings increased to $4.33 billion, or $1.51 per share, from $3.83 billion, or $1.33 per share, a year earlier.
Earnings, adjusted for non-recurring litigation and other costs, came to $1.66 per share. Analysts surveyed by Zacks Investment Research expected $1.54 per share, on average.
The maker of Band-Aids, medical devices and biologic drugs said revenue rose 9.1 percent to $19.5 billion from $17.88 billion a year ago. Analysts expected $18.85 billion.
The company "seems to have turned the corner on its string of unpleasant surprises, and is delivering mostly positive surprises," said Erik Gordon, a professor and analyst at University of Michigan's Ross School of Business.
Continue reading this story on the...